Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-13T02:26:20.417Z Has data issue: false hasContentIssue false
  • English
  • Français

Radical hypofractionated radiotherapy for the treatment of non-small-cell lung cancer using 52·5–55 Gy in 20 fractions: the North Wales Cancer Centre experience

Published online by Cambridge University Press:  25 March 2015

Niladri Ghosal ,
Anna P. Mullard ,
Nafisa M. Chowdhury ,
Mark O’Beirn ,
Claire Fuller ,
Ravi Kodavatiganti ,
Glyn Thomas ,
Nick Smith  and
Angel Garcia
Niladri Ghosal
Affiliation:
Betsi-Cadwaladr University Health Board, North Wales Cancer Treatment Centre, Glan Clwyd Hospital, Rhyl, UK
Anna P. Mullard*
Affiliation:
Betsi-Cadwaladr University Health Board, North Wales Cancer Treatment Centre, Glan Clwyd Hospital, Rhyl, UK
Nafisa M. Chowdhury
Affiliation:
Betsi-Cadwaladr University Health Board, North Wales Cancer Treatment Centre, Glan Clwyd Hospital, Rhyl, UK
Mark O’Beirn
Affiliation:
Betsi-Cadwaladr University Health Board, North Wales Cancer Treatment Centre, Glan Clwyd Hospital, Rhyl, UK
Claire Fuller
Affiliation:
Betsi-Cadwaladr University Health Board, North Wales Cancer Treatment Centre, Glan Clwyd Hospital, Rhyl, UK
Ravi Kodavatiganti
Affiliation:
Betsi-Cadwaladr University Health Board, North Wales Cancer Treatment Centre, Glan Clwyd Hospital, Rhyl, UK
Glyn Thomas
Affiliation:
Betsi-Cadwaladr University Health Board, North Wales Cancer Treatment Centre, Glan Clwyd Hospital, Rhyl, UK
Nick Smith
Affiliation:
Betsi-Cadwaladr University Health Board, North Wales Cancer Treatment Centre, Glan Clwyd Hospital, Rhyl, UK
Angel Garcia
Affiliation:
Betsi-Cadwaladr University Health Board, North Wales Cancer Treatment Centre, Glan Clwyd Hospital, Rhyl, UK
*
Correspondence to: Anna P. Mullard, Betsi Cadwaladr University Health Board, North Wales Cancer Treatment Centre, Glan Clwyd Hospital, Rhyl LL18 5UJ, UK. Tel: 44 124 838 4150. Fax: 44 174 544 5212. E-mail: anna.mullard@wales.nhs.uk
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Radical hypofractionated thoracic radiotherapy is the most commonly used radiotherapy schedule for inoperable non-small-cell lung cancer (NSCLC) in the United Kingdom, despite a lack of level I evidence to support its use.

Purpose

To supplement existing published retrospective data with a mature data series and provide further evidence to support the use of this schedule in routine clinical practice.

Materials and methods

Retrospective analysis of all inoperable NSCLC cases treated with radical hypofractionated radiotherapy with or without induction chemotherapy in the North Wales Cancer Treatment Centre between 2001 and 2011.

Results

Of the 222 patients, 209 (94%) received 55 Gy in 20 fractions (#) and 13 (6%) received 52·5 Gy in 20#. Induction chemotherapy was administered in 121 (55%) cases. The median survival of 28·6 months (95% confidence interval 24·2–32·5) is comparable with previously published survival outcomes for this patient group.

Conclusion

The growing body of evidence for this schedule, confirming survival outcomes comparable with internationally accepted results, is sufficient to support its future use in inoperable NSCLC.

Keywords

52.5-55Gy in 20 fractionshypofractionatednon-small-cell lung cancerradicalradiotherapy
Type
Original Articles
Information
Journal of Radiotherapy in Practice , Volume 14 , Issue 3 , September 2015 , pp. 268 - 273
Check for updates
Copyright
© Cambridge University Press 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Prewett, S L, Aslam, S, Williams, M Vet al. The management of lung cancer: a UK survey of oncologists. Clin Oncol (R Coll Radiol) 2012; 24 (6): 402–409.CrossRefGoogle ScholarPubMed
2.National Institute for Health and Care Excellence. Lung Cancer: The Diagnosis and Treatment of Lung Cancer. CG121. London: NICE, 2011.Google Scholar
3.Price, A, Yellowlees, A, Russell, Set al. Radical radiotherapy with or without gemcitabine in patients with early stage medically inoperable non-small cell lung cancer. Lung Cancer 2012; 77: 532–536.CrossRefGoogle ScholarPubMed
4.Maguire, J, Khan, I, McMenemin, Ret al. SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status. Eur J Cancer 2014; 50: 2939–2949.CrossRefGoogle ScholarPubMed
5.Withers, H R, Taylor, J M, Maciejewski, B. The hazard of accelerated tumour clonogen repopulation during radiotherapy. Acta Oncol 1988; 27: 131–146.CrossRefGoogle ScholarPubMed
6.Williams, M V, Drinkwater, K J. Geographical variation in radiotherapy services across the UK in 2007 and the effect of deprivation. Clin Oncol (R Coll Radiol) 2009; 21 (6): 431–440.CrossRefGoogle ScholarPubMed
7.Morita, K, Fuwa, N, Suzuki, Yet al. Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I: a retrospective analysis of 149 patients. Radiother Oncol 1997; 42 (1): 31–36.CrossRefGoogle Scholar
8.Lester, J F, Macbeth, F R, Brewster, A Eet al. CT-planned accelerated hypofractionated radiotherapy in the radical treatment of non-small cell lung cancer. Lung Cancer 2004; 45 (2): 237–242.CrossRefGoogle ScholarPubMed
9.Gauden, S, Ramsay, J, Tripcony, L. The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung. Chest 1995; 108 (5): 1278–1282.CrossRefGoogle Scholar
10.Low, J Sh, Koh, W Y, Yap, S P, Fong, K W. Radical radiotherapy in stage I non-small cell lung cancer (NSCLC)-Singapore National Cancer Centre experience. Ann Acad Med Singapore 2007; 36 (9): 778–783.CrossRefGoogle Scholar
11.Pemberton, L S, Din, O S, Fisher, P M, Hatton, M Q. Accelerated radical radiotherapy for non-small cell lung cancer using two common regimens: a single-centre retrospective study of outcome. Clin Onco (R Coll Radiol) 2009; 21 (3): 161–167.CrossRefGoogle ScholarPubMed
12.Campeau, M P, Herschtal, A, Wheeler, Get al. Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2009; 74 (5): 1371–1375.CrossRefGoogle ScholarPubMed
13.Anderson, W J A, McAleer, J J A, Stranex, S, Prescott, G. Radical radiotherapy for inoperable non-small cell lung cancer: what factors predict prognosis? Clin Oncol (R Coll Radiol) 2000; 12 (1): 48–52.Google ScholarPubMed
14.Din, O S, Harden, S V, Hudson, Eet al. Accelerated hypo-fractionated radiotherapy for non small lung cancer: results from 4 UK centres. Radiother Oncol 2013; 109: 8–12.CrossRefGoogle ScholarPubMed
15.Saunders, M, Dische, S, Barrett, Aet al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. Radiother Oncol 1999; 52 (2): 137–148.CrossRefGoogle ScholarPubMed
16.Goldstraw, P, Crowley, J, Chansky, Ket al. The IASLC lung cancer staging project; proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2 (8): 706–714.CrossRefGoogle ScholarPubMed
17.Lipford, E H 3rd, Eggleston, J C, Lillemoe, K Det al. Prognostic factors in surgically resected limited-stage, non-small cell carcinoma of the lung. Am J Surg Pathol 1984; 8 (5): 357–365.CrossRefGoogle Scholar
18.Takise, A, Kodama, T, Shimosato, Yet al. Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter. Cancer 1988; 61 (10): 2083–2088.3.0.CO;2-U>CrossRefGoogle ScholarPubMed
19.Royal College of Radiologists. Radiotherapy Dose-Fractionation: 4.8 Lung Cancer. London: RCR, 2006.Google Scholar
20.Scottish Intercollegiate Guidelines Network. Management of Lung Cancer. (SIGN Publication No. 137). Edinburgh: SIGN, 2014.Google Scholar